Advertisement

Systematic Review of G3T1 Bladder Cancer

  • Sanchia S. GoonewardeneEmail author
  • Raj Persad
  • Hanif Motiwala
  • David Albala
Chapter

Abstract

High grade bladder cancer is an aggressive disease. The management of G3T1 disease is controversial. This chapter covers systematic review results.

References

  1. Badalato GM, Gaya JM, Hruby G, Patel T, Kates M, Sadeghi N, Benson MC, McKiernan JM. Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference? BJU Int. 2012;110(10):1471–7.CrossRefGoogle Scholar
  2. Bogdanović J, Marusić G, Djozić J, Sekulić V, Budakov P, Dejanović N, Stojkov J. The management of T1G3 bladder cancer. Urol Int. 2002;69(4):263–5.CrossRefGoogle Scholar
  3. Boström PJ, Alkhateeb S, van Rhijn BW, Kuk C, Zlotta AR. Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Expert Rev Anticancer Ther. 2010;10(12):1891–902.CrossRefGoogle Scholar
  4. Canter D, Egleston B, Wong YN, Smaldone MC, Simhan J, Greenberg RE, Uzzo RG, Kutikov A. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis. Urol Oncol. 2013;31(6):866–70.CrossRefGoogle Scholar
  5. Chamie K, Ballon-Landa E, Daskivich TJ, Bassett JC, Lai J, Hanley JM, Konety BR, Litwin MS. Saigal CS Treatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancer. Urol Oncol. 2015;33(1):20.e9–17.CrossRefGoogle Scholar
  6. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015;67(1):74–82.CrossRefGoogle Scholar
  7. Jerlström T, Gårdmark T, Carringer M, Holmäng S, Liedberg F, Hosseini A, Malmström PU, Ljungberg B, Hagberg O, Jahnson S. Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. Scand J Urol. 2014;48(4):334–40.CrossRefGoogle Scholar
  8. Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med. 2007;4(9):e284.CrossRefGoogle Scholar
  9. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010;57(1):60–70.CrossRefGoogle Scholar
  10. Lida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience. Int J Urol. 2009;16(3):287–92.CrossRefGoogle Scholar
  11. Lipsker A, Hammoudi Y, Parier B, Drai J, Bahi R, Bessede T, Patard JJ, Pignot G. Should we propose a systematic second transurethral resection of the bladder for all high-risk non-muscle invasive bladder cancers? Prog Urol. 2014;24(10):640–5.CrossRefGoogle Scholar
  12. Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG. The role of radical cystectomy in the management of high grade NMI bladder cancer (PA, P1, PIS and P2). Urol. 1990;144(3):641–5.CrossRefGoogle Scholar
  13. Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol. 2014;66(4):694–701.CrossRefGoogle Scholar
  14. Orsola A, Werner L, de Torres I, Martin-Doyle W, Raventos CX, Lozano F, Mullane SA, Leow JJ, Barletta JA, Bellmunt J, Morote J. Re-examining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer. 2015;112(3):468–74.CrossRefGoogle Scholar
  15. Páez Borda A, Luján Galán M, Gómez de Vicente JM, Moreno Santurino A, Abate F, Berenguer Sánchez A. Preliminary results of the treatment of high grade (T1G3) NMI tumors of the bladder with transurethral resection. Actas Urol Esp. 2001;25(3):187–92.CrossRefGoogle Scholar
  16. Sanseverino R, Napodano G, Campitelli A, Addesso M. Prognostic impact of ReTURB in high grade T1 primary bladder cancer. Arch Ital Urol Androl. 2016;88(2):81–5.CrossRefGoogle Scholar
  17. Thomas F, Rosario DJ, Rubin N, Goepel JR, Abbod MF, Catto JW. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm? Cancer. 2012;118(22):5525–34.CrossRefGoogle Scholar
  18. Thomas F, Noon AP, Rubin N, Goepel JR, Catto JW. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol. 2013;63(1):145–54.CrossRefGoogle Scholar
  19. van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60(3):493–500.CrossRefGoogle Scholar
  20. Yang GL, Zhang LH, Liu Q, Wang ZL, Duan XH, Huang YR, Bo JJ. A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience. Urol Oncol. 2017;35(2):38.e9–15.CrossRefGoogle Scholar
  21. Zhang Y, Xie L, Chen T, Xie W, Wu Z, Xu H, Xing C, Sha N, Shen Z, Qie Y, Liu X, Hu H, Wu C. Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study. Onco Targets Ther. 2016;28(9):605–11.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sanchia S. Goonewardene
    • 1
    Email author
  • Raj Persad
    • 2
  • Hanif Motiwala
    • 3
  • David Albala
    • 4
  1. 1.East of England DeaneryNorfolk and Norwich University HospitalNorwichUK
  2. 2.North Bristol NHS TrustBristolUK
  3. 3.Southend University HospitalWestcliff-on-SeaUK
  4. 4.Boston UniversityBostonUSA

Personalised recommendations